GlaxoSmithKline received approval from the FDA to market Boostrix for adults. The vaccine, which is designed to protect against tetanus, diphtheria and pertussis (whooping cough), was previously approved for ages 10-18. GSK now has the green light to use the booster in adults ages 19-64 as well. Boostrix will join a line of GSK vaccines for adults which also include vaccines against hepatitis A and B and the flu. Release